Ventricular Assist Device Therapy for Heart Failure—Past, Present, and Future

L. Bellumkonda,P. Bonde

DOI: https://doi.org/10.1097/AIA.0b013e31826233a9

International Anesthesiology Clinics

Abstract:Congestive heart failure (CHF) is a complex clinical syndrome characterized by cardiac dysfunction with impaired organ perfusion and/or venous congestion. CHF has emerged as a major chronic disease among patients in the United States (USA), accounting for over 10 million office visits, 6 million hospital days, and $30 billion in direct costs each year. The current prevalence of CHF in the USA is in excess of 5 million, with estimates of future prevalence as high as 10 million within the next decade. Advances in pharmaceutical and surgical therapy have improved quality of life and survival for Class II and III heart failure, however many patients progress to the advanced stages of CHF. Mortality is high with advanced CHF; the annual mortality rate is 50-75% for patients with New York Heart Association (NYHA) class IV heart failure (HF). Cardiac transplantation has become the gold standard of therapy for a subset of patients with advanced CHF. Its use is limited, however, by donor availability, strict recipient selection criteria, and long-term complications from the transplant and the immunosuppressive agents. This resulted in increased use of ventricular assist devices (VADs) as a “bridge to transplantation” or as “destination therapy”. Initial studies indicate that patients supported with VADs had decreased mortality, better quality of life, and a superior outcome when compared to patients managed with optimal medical therapy, including inotropic agents. VAD use is itself limited, however, by the physical,